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Abstract
Chemerin is a recently discovered adipokine with inflammatory and metabolic actions 
relevant for chronic disease development. However, evidence from human research on 
the role of chemerin in chronic disease risk is still lacking. We assessed the reliability 
of plasma chemerin concentrations measured on two occasions over a 4-month period 
in 207 apparently healthy participants. In addition, we explored the cross-sectional 
associations between chemerin and inflammatory biomarkers using Spearman partial 
correlation and multivariable linear regression analyses. Intra-individual reproducibility 
of chemerin measurements was assessed by calculating intraclass correlation coefficients 
(ICCs) and exploration of Bland–Altman plots. Reliability analyses revealed good 
reproducibility of chemerin measurements (ICC: 0.72 (95%-CI 0.65, 0.78)). Visual 
inspection of Bland–Altman plots confirmed that the two time point measurements had 
a high level of agreement. In correlation analyses, chemerin was positively correlated 
with adiposity measures (body mass index and waist circumference). In addition, 
independent of adiposity measures, chemerin was correlated with the biomarkers 
C-reactive protein, fatty acid-binding protein 4 and progranulin (Rho-s ranging from 
0.23 to 0.37). In multivariable linear regression analysis, a combination of correlated 
factors including body mass index, waist circumference, C-reactive protein, progranulin 
and fatty acid-binding protein-4 explained 28.0% of chemerin concentrations. These 
findings demonstrate methodological utility of chemerin concentrations in population-
based research setting. Human studies are highly warranted in order to provide further 
insights into the role of chemerin as a biomarker linking immunity and metabolism in 
relation to chronic disease risk.
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Chemerin, also known as tazarotene-induced gene 2 
protein (TIG2) and retinoic acid receptor responder 2 
(RARRES2), is a 14-kDa chemoattractant protein known 
to modulate immune system function through its binding 
to the chemerin receptor ChemR23 (1). It is secreted 
in an inactive form as prochemerin and is activated 
through cleavage of the C-terminus by inflammatory and 
coagulation serine proteases. Animal studies indicated 
visceral adipose tissue, placenta and liver, and to a lesser 
extent lungs, heart, ovaries, kidneys and pancreas as main 
anatomical sites of chemerin production (2, 3). Chemerin 
was initially identified as a retinoid-responsive gene present 
in psoriatic skin lesions in 1997 using differential display 
(4). Ten years later (in 2007) chemerin was re-discovered 
as a novel adipokine regulating adipogenesis and genes 
critical in glucose and lipid metabolism of adipocytes 
(3). Subsequent research characterized additional roles 
of chemerin in diverse biological processes including 
cell proliferation and differentiation, angiogenesis, renal 
function and energy metabolism (3, 5, 6, 7). Collectively, 
chemerin could be distinguished as an immune marker 
acting as a chemoattractant agent promoting the 
recruitment of immune cells to lymphoid organs and sites 
of tissue damage and as autocrine/paracrine signaling 
agent that is involved in several metabolic and cell-
developmental processes particularly in adipocytes (8). 
Higher circulating chemerin concentrations have been 
reported in patients suffering from systemic inflammatory 
diseases such as Crohn’s disease, ulcerative colitis (9), liver 
diseases (10), chronic pancreatitis (11) and polycystic 
ovary syndrome (12). Cross-sectional studies reported 
associations between chemerin and biomarkers of 
inflammation, metabolic parameters and anthropometric 
measures of adiposity (13). However, little is known about 
the interrelations of chemerin with inflammation-related 
adipokines. Particularly, there have been no studies based 
on human population samples.
In summary, recent research has uncovered chemerin 
as an adipokine implicated in immune, inflammatory and 
obesity-related pathophysiological conditions. However, 
no data from large-scale prospective population-based 
studies exist to support or refute generated hypothesis 
on chemerin involvement in disease development. 
Important prerequisite for planning biomarker 
assessment in a prospective study is the assessment of 
whether single biomarker measurements, as done in most 
epidemiological research settings, are stable over time 
and not affected by biological variability (14). So far, the 
reliability of chemerin as biomarker in human research 
has not been evaluated. To fill this gap, we aimed to assess 
the intra-individual reproducibility of plasma chemerin 
concentrations over a 4-month interval using data from 
a sample of apparently healthy participants within the 
European Prospective Investigation into Cancer and 
Nutrition (EPIC) Potsdam Study. As a secondary aim, we 




The EPIC-Potsdam Study is part of the multicenter 
prospective cohort study EPIC, which was designed to 
investigate the association between nutrition, cancer and 
other chronic diseases (15). In Potsdam, Germany, 27,548 
participants (16,644 women aged 35–65 years and 10,904 
men aged 40–64) were recruited between 1994 and 1998 
(16). The present study was based on a randomly selected 
sample from all participants of the EPIC-Potsdam Study 
population (17). Exclusion criteria included history of 
heart disease and stroke (myocardial infarction, heart 
failure, cardiomyopathy and angina pectoris), impaired 
mobility, current therapy with β-blockers or systolic or 
diastolic blood pressure above 180 mmHg or 110 mmHg, 
respectively. Of the initially invited 407 participants, 11 
did not respond to the invitation, 176 declined study 
participation. Twelve participants were additionally 
excluded due to reported therapy of β-blockers. From 
the remaining participants, all but one provided blood 
samples leading to a total sample size of 207 participants 
(124 women and 83 men). Blood samples were collected on 
two occasions 4 months apart with the first in the period 
of October 2007–March 2008 and the second between 
February and July 2008. Timing of blood collection was, 
with few exceptions, 08:00–11:00 h, with ca. 10% of 
participants not being fasted. All participants provided 
written informed consent and the study procedures 
were approved by the Ethics Committee of the Medical 
Association of the State of Brandenburg.
Biomarker measurements
On two occasions, four months apart, blood was drawn, the 
fractions separated and stored at −80°C. With the exception 
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of high-sensitivity C-reactive protein (hsCRP), which was 
measured in serum, concentrations of chemerin, fatty acid-
binding protein 4 (FABP-4), monocyte chemoattractant 
protein 1 (MCP-1), omentin-1, progranulin and vaspin 
were measured in EDTA-plasma. All biomarkers were 
measured with commercially available sandwich enzyme-
linked immunosorbent assays (ELISA) (BioVendor, Kassel, 
Germany) according to the manufacturer’s instructions. 
Repeated samples of each participant were measured in 
the same analytical batch. Measurements of chemerin 
and omentin-1 were performed at the Institute of Clinical 
Chemistry, University Magdeburg. Manufacturer’s 
specified average intra- and inter-assay coefficients 
of variation (CV) for chemerin were 6.0% and 7.6%, 
respectively. Inter-assay CV based on our data was 5.9%. 
Measurements of hsCRP in serum and FABP-4, MCP-1, 
progranulin and vaspin in plasma were performed in 
the Department of Clinical Nutrition, German Institute 
of Human Nutrition Potsdam-Rehbrücke, Germany. 
The intra- and inter-individual CVs of hsCRP were 5.1% 
and 6.1%, respectively as reported by the manufacturer. 
Based on our data, the inter-individual CV was 11.0%. 
Due to insufficient serum volume, hsCRP could only be 
measured in a reduced number of participants (n = 151). 
Detailed information on the measurements of plasma 
FABP-4, MCP-1, omentin-1, progranulin and vaspin 
concentrations have been reported elsewhere (18, 19).
Statistics
Non-normally distributed data were transformed using 
the natural logarithm in order to allow the application 
of parametric tests and the calculation of mean 
concentrations. Non-normality was determined by visual 
inspection of the histogram and quantile–quantile plot 
evaluation. Mean chemerin concentrations are presented 
as geometric means. Strata-specific mean concentrations 
were calculated for sex, BMI (<25 kg/m2 vs ≥25 kg/m2), 
waist circumference (♂: <94 cm vs ≥94 cm, ♀: <80 cm 
vs ≥80 cm) and inflammatory status represented by 
hsCRP concentration (below sample median vs above 
median). A random-effects analysis of variance (ANOVA) 
with chemerin concentration as dependent variable 
and study participant as explanatory variable was 
used to estimate the variance components explained 
by within-person and between-person differences, 
respectively. Overall and strata-specific intraclass 
correlation coefficients (ICCs) were calculated as ratios of 
between-person variance and total variance (between-
person variance + within-person variance).
To compare mean chemerin concentrations between 
sampling time points and between categories within 
one sampling time point, paired and unpaired two-
sided Student’s t-tests were applied. In addition to 
ICCs, reliability was also evaluated by inspection of 
Bland–Altman plots as a recommended complementing 
procedure to assess the agreement of two measurements 
for each participant (20). To evaluate interdependence 
with the individual characteristics, the ICCs were 
calculated across the above defined strata (sex, BMI, waist 
circumference and hsCRP levels). Following established 
cut points, estimated reproducibility is rated as excellent 
(ICCs ≥0.75), good (ICC: 0.74–0.60), fair (ICC: 0.59–0.40) 
or poor (ICCs <0.40). In sensitivity analyses, ICCs were 
calculated after excluding participants with extreme 
chemerin measurement values (values within 1st or 
above 99th percentile) and non-fasting participants at 
blood sampling. Using linear regression, we examined the 
influence of time of day at blood draw taking into account 
age, sex, fasting status at blood draw and BMI.
Correlation of chemerin with anthropometric 
measures of adiposity (BMI and waist circumference) and 
selected biomarkers, including hsCRP, FABP-4, MCP-1, 
omentin-1, progranulin and vaspin were evaluated using 
Spearman partial correlation analyses adjusted for age 
and sex. Correlation analyses with the biomarkers were 
additionally adjusted for BMI. Fisher’s z transformation 
was used to produce 95% confidence intervals for each 
correlation coefficient. In linear regression analyses, we 
modeled anthropometric measures and biomarkers as 
predictors of chemerin concentrations to estimate the 
explained variance represented by the adjusted coefficient 
of determination (adjusted R2). Adjusted R2 takes into 
account the number of predictors in the model, which 
automatically would increase the explained variance with 
every additionally included variable without actually 
having a predictive value. In correlation and regression 
analyses anthropometric indices and biomarker 
concentrations of the first (baseline) measurement were 
used as these did not substantially differ from the second 
measurement. We also calculated the degree of attenuation 
of hypothetical relative risk estimates (RR) that could 
arise due to biological variability of chemerin based on 




) . All 
statistical analyses were performed in SAS (version 9.4, 
Enterprise Guide 6.1, SAS Institute Inc., Cary, NC, USA).
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Table 2 Overall and stratified concentrations (geometric mean (95%-CI)) in ng/mL for measurements taken 4 months apart 
and ICCs.
 N First measurement Second measurement P differenceA ICCC
All 207 161.0 (156.0, 166.0) 155.6 (150.5, 160.9) 0.005 0.72 (0.65, 0.78)
Sex      
 Men 83 163.4 (155.1, 172.0) 155.5 (147.6, 163.8) 0.01 0.73 (0.61, 0.82)
 Women 124 159.4 (153.3, 165.7) 155.7 (149.1, 162.7) 0.14 0.72 (0.63, 0.80)
 P differenceB  0.45 0.97   
BMI      
 <25 kg/m2 81 145.8 (139.3, 152.7) 139.3 (133.2, 145.7) 0.004 0.75 (0.64, 0.83)
 ≥25 kg/m2 126 171.5 (165.1, 178.2) 167.1 (160.2, 174.3) 0.13 0.64 (0.54, 0.74)
 P differenceB  <0.001 <0.001   
Waist circumference      
 ♀: <80 cm, ♂: <94 cm 56 141.2 (134.7, 148.0) 136.5 (129.6, 143.9) 0.04 0.78 (0.65, 0.86)
 ♀: ≥80 cm, ♂: ≥94 cm 151 169.0 (163.0, 175.2) 163.4 (157.2, 169.8) 0.03 0.66 (0.57, 0.75)
 P differenceB  <0.001 <0.001   
hsCRPD      
 Below median 70 149.8 (143.2, 156.8) 145.1 (138.1, 152.5) 0.04 0.78 (0.67, 0.86)
 Above median 71 170.3 (161.3, 179.7) 164.3 (155.3, 173.9) 0.05 0.78 (0.68, 0.86)
 P differenceB  <0.001 <0.001   
APaired two-sided t-test to compare concentrations between first and second measurement. BUnpaired two-sided t-test to compare concentrations 
between strata for sex, age, waist circumference and hsCRP levels. CICC defined as ratio of between-person variance and total variance. DMedian hsCRP 
concentration = 1.27 μg/mL, reduced number of participants due to insufficient serum volume.



















Table  1 presents baseline characteristics of the study 
population. The mean (s.d.) age of the participants was 
56.5 (4.2)  years. On average, participants had a BMI of 
26.0 (4.0) kg/m2 and a WC of 93.0 (12.8) cm. BMI and 
waist circumference measurements were stable over the 
period of 4 months (ICC = 0.99, ICC = 0.98, respectively).
Table 2 presents overall and strata-specific chemerin 
concentrations and ICCs. Chemerin concentrations were 
higher in participants with higher BMI (≥25 kg/m2), WC 
(♀: ≥80 cm, ♂: ≥94 cm) and hsCRP (above 1.3 μg/mL) 
Table 1 Baseline characteristics of the study population, overall and by sexA.
 All participants (n = 207) Men (n = 83) Women (n = 124)
Age (years) 56.5 (4.2) 58.0 (3.1) 55.4 (4.5)
 Range 44.8–63.9 51.5–63.7 44.83–63.9
BMI (kg/m2) 26.5 (4.0) 27.6 (3.5) 25.8 (4.1)
 Range 19.1–41.7 19.8–37.0 19.1–41.7
Waist circumference (cm) 93.0 (12.8) 101.7 (10.3) 87.1 (10.7)
 Range 68.3–126.4 79.3–126.4 68.3–115.8
Non-fasting (%) 10 13 8
Chemerin (ng/mL) 159 (137, 186) 162 (139, 186) 156 (135, 188)
 Range 82.4–283 82.4–283 105–278
hsCRP (μg/mL)B 1.24 (0.65, 2.45) 1.52 (0.72, 2.90) 1.10 (0.58, 2.21)
 Range 0.14–13.4 0.14–12.9 0.16–13.4
FABP-4 (ng/mL) 22.8 (17.5, 27.6) 19.7 (15.1, 23.4) 25.4 (20.8, 30.4)
 Range 0.25–55.0 8.0–54.9 0.25–55.0
MCP-1 (ng/mL) 0.44 (0.35, 0.53) 0.43 (0.36, 0.51) 0.44 (0.34, 0.54)
 Range 0.15–1.62 0.19–1.32 0.15–1.62
Omentin-1 (ng/mL) 382 (313, 467) 362 (306, 433) 396 (319, 492)
 Range 99.4–945 99.4–945 163–789
Progranulin (pg/mL) 30.8 (26.35, 36.14) 32.8 (26.3, 38.4) 30.2 (26.4, 34.6)
 Range 0.40–61.0 0.40–61.0 0.45–59.5
Vaspin (ng/mL) 0.20 (0.14, 0.32) 0.18 (0.12, 0.22) 0.24 (0.15, 0.36)
 Range 0.03–7.08 0.03–5.61 0.04–7.08
AValues are expressed as arithmetic means (s.d.), medians (25th, 75th percentile) or percentages. BReduced number of participants due to insufficient 
serum volume.
FABP-4, fatty acid-binding protein-4; hsCRP, high-sensitivity C-reactive protein; MCP-1, monocyte chemoattractant protein 1.
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Bland–Altman plot. Agreement of repeated measurements (y-axis) in 
relation to average concentrations (x-axis) for each individual (n = 207). 
Agreement was calculated as difference between the two measurements 
(t2–t1) for each individual. 95% confidence bounds represent the 
expected range of differences based on the average difference. Values of 
one participant were excluded from the figure, but not from calculation 
of mean difference and 95% CI, to improve the legibility of the figure. 
Values for this participant were individual difference = 297.7 (ng/mL), 











hsCRP FABP-4 MCP-1 Omentin-1 Progranulin Vaspin
Figure 2
Spearman correlation coefficients (95% CI) for chemerin with 
inflammation-related biomarkers adjusted for age, sex, BMI and mutually 
with remaining biomarkers. Analysis based on n = 151 due to insufficient 
serum volume for hsCRP measurements. 95% CI calculated using Fisher’s z 
transformation. FABP-4, fatty acid-binding protein-4; hsCRP,  




















Percentages of explained variance (represented by adjusted R2) of 
chemerin concentrations. Adjusted R2 was derived from linear regression 
models with chemerin concentrations as dependent variable and 
anthropometric measures and biomarker concentrations as independent 
variables. Models are based on data of participants with available hsCRP 
measurements (n = 151). Adjusted R2, adjusted coefficient of 
determination; FABP-4, fatty acid-binding protein-4; hsCRP, high-
sensitivity C-reactive protein; WC, waist circumference.


















compared to lower strata. The overall ICC of a 4-month 
period was 0.72 (95%-CI: 0.65, 0.78), indicating ‘good’ 
reliability. Strata-specific ICCs did not substantially differ 
between the sexes and according to strata of BMI, WC 
and hsCRP levels staying within the interval of ‘good’ 
reliability (Table 2). Information from the Bland–Altman 
plots (Fig.  1) essentially confirmed a good agreement 
and symmetric distribution of the measurements. Using 
the overall ICC (0.72), hypothetical true risk estimates 
would be attenuated by ca. 11% (RRtrue = 1.5), 23% 
(RRtrue = 2.5) and 30% (RRtrue = 3.5) due to intra-individual 
chemerin variability. Sensitivity analyses showed a 
slight improvement of the ICC (0.77 (0.71, 0.82)) when 
participants with extreme (within 1st or above 99th 
percentile) chemerin concentrations were excluded. The 
ICC did not change when non-fasted participants were 
excluded, while in non-fasted participants the ICC was 
slightly reduced (0.70 (0.48, 0.84)). Linear regression 
analyses of chemerin concentrations according to time 
of day showed no effect at both sampling time points 
(beta coefficients corresponding to change of chemerin 
concentration (ng/mL) per hour of day (95% CI): 1st: 0.73 
(−5.94; 7.40), 2nd: 2.69 (−4.41; 9.78)).
We observed higher chemerin concentrations in 
obese participants as compared to non-obese (Table  2). 
Chemerin concentrations were also positively correlated 
with BMI (rho = 0.35 (95%-CI: 0.22, 0.47)) and waist 
circumference (0.37 (0.24, 0.48)). However, when adjusting 
for hsCRP and adipokines the correlations were greatly 
attenuated (BMI: 0.12 (−0.05, 0.28), waist circumference: 
0.16 (0.00, 0.32)). Chemerin showed a correlation with 
hsCRP (0.26 (0.10, 0.41)), as well as with the adipokines 
FABP-4 (0.28 (0.12, 0.42)) and progranulin (0.23 (0.07, 
0.38)), when adjusted for age, sex and BMI. No correlation 
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was observed with MCP-1, omentin-1 and vaspin. Mutual 
adjustments did not essentially change the correlations of 
the biomarkers with chemerin (Fig. 2). Linear regression 
analyses showed that the addition of hsCRP to a model 
including BMI and waist circumference (adjusted 
R2 = 14.6%) increased explained variance of chemerin 
concentrations by 7.0 percentage points (Fig.  3). 
Additionally including progranulin or FABP-4 produced 
even further increase in explained variance by 1.6 and 
4.9 percentage points indicating FABP-4 and progranulin 
as independent predictors of chemerin concentrations. 
A model comprising all mentioned variables (BMI, waist 
circumference, hsCRP, progranulin and FABP-4) resulted 
in 28.0% explained variance.
Discussion
Here, we provide first results for the reliability of chemerin. 
Our data suggest that chemerin measurements have a good 
reproducibility over a 4-month time period indicating 
that single chemerin measurements in prospective studies 
would be suitable and informative for research. In addition, 
we report for the first time on interrelations between 
chemerin and inflammation-related adipokines. Taken 
together, the data support further prospective studies 
aimed at improving our understanding of chemerin actions 
in humans and its potential role in the pathogenesis of 
inflammation-related diseases and conditions.
Chemerin has been proposed to play a role as 
adipokine (21), chemokine (22) and a growth factor 
(23). Although the different pathways are intertwined, 
chemerin’s implication in inflammatory processes seems 
particularly attractive. Inflammation-related adipokines in 
general have been suggested to pose a link between excess 
fat mass, adipose tissue inflammation and chronic diseases 
and chemerin could therefore play a prominent role in 
this regard. In line with previous research, we observed 
higher chemerin concentrations in obese participants 
as compared to non-obese (24). Expectedly, chemerin 
concentrations were also positively correlated with BMI 
and WC independent of participants’ age and sex.
Correlation of circulating chemerin levels with markers 
of low-grade chronic inflammation, such as CRP (24), 
further hint at chemerin’s involvement in inflammatory 
pathways. In addition to CRP and going beyond what 
has been shown in humans so far, we showed positive 
associations with the inflammation-related adipokines 
FABP-4 and progranulin. Similar to chemerin, these 
biomarkers were shown to exhibit elevated circulating 
concentrations in obesity, but also to represent activated 
immune response due to infection and inflammation 
(25, 26) and act in a pro-inflammatory fashion (27, 28). 
Importantly, FABP-4 and progranulin were independent 
predictors of chemerin concentrations even beyond 
BMI, WC and CRP. These data potentially uncover an 
important interrelation between inflammation-related 
adipokines that deserve further exploration and careful 
interpretation. Revealed correlations both with obesity 
and inflammatory biomarkers essentially add to the 
growing body of evidence implicating chemerin as a 
biomarker linking immunity and metabolism in relation 
to chronic disease risk and point to pathways implicated 
in adipokine production beyond adiposity per se.
Our study has several strengths. The study population 
was reasonably large for a validation sample and included 
both sexes in acceptable proportions. However, the 
used study population does not allow an unconditional 
generalization of our results due to specific ethnicity, age 
range and apparent healthiness of the participants. Future 
studies should therefore take into account any differences 
in assays, laboratories, sample types, storage time, repeated 
samplings and timing of blood draw. However, regarding 
the last point, timing of blood draw in this study was 
preferably conducted in the morning, with only few 
exceptions. In addition, we explored the potential effect 
of time of the day at blood draw and found no influence.
In summary, we found chemerin to be a reliable 
biomarker potentially linking immunity and metabolism. 
This supports the conduct of prospective studies to further 
the understanding of chemerin’s role in the development 
of chronic diseases.
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